 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Sanofi India Standalone June 2023 Net Sales at Rs 706.10 crore, up 0.97% Y-o-Y

Sharekhan is bullish on Sanofi India has recommended buy rating on the stock with a target price of Rs 7500 in its research report dated May 18, 2023.

Buy Sanofi India; target of Rs 7500: Sharekhan

Sanofi India will hold a meeting of the Board of Directors of the Company on 10 May 2023.

Sanofi India to conduct board meeting

On 16 September 2022, the company had informed that the the Ministry of Health and Family Welfare, Government of India, had released the revised National List of Essential Medicines (NLEM), 2022 which included the companys product insulin glargine (100 IU ml) as part of the said list and subsequently the National Pharmaceutical Pricing Authority (NPPA) will fix the ceiling price for the cost to patients of the products included in the list.In an exchange filing made after trading hours yesterday, Sanofi India announced that the NPPA has now issued the list to fix the ceiling price for the cost to patients of its insulin glargine brand Lantus and accordingly the said product will be subject to a price reduction of approximately 21% on a weighted average basis considering the different SKUs being marketed by the company.While there will be an impact on sales, the company does not expect a material impact on the profitability considering the arms-length operating model principle being followed with regard to sourcing of this product from Sanofi Group. The drop in price is also likely to result in some volume traction in Lantus especially in the second half of the year,” Sanofi India said in a statement.Sanofi India is one of the entities through which Sanofi operates in India. It offers a wide array of medicines for therapy areas such as diabetes, cardiology, thrombosis, central nervous system and anti-histamines. The products manufactured by the company are distributed in India and exported to many developed as well as developing countries.The companys net profit surged 44.8% to Rs 130.9 crore in Q4 CY22 from Rs 90.40 crore in Q4 CY21. Revenue from operations fell 2.3% year on year (YoY) to Rs 671.90 crore in the quarter ended 31 December 2022.The scrip shed 0.44% to currently trade at Rs 5965.30 on the BSE.

Sanofi's insulin glargine to witness price reduction of 21%

Sanofi India Ltd is up for a fifth straight session today. The stock is quoting at Rs 6004.4, up 1.38% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 0.45% on the day, quoting at 17677.5. The Sensex is at 60068.87, up 0.39%. Sanofi India Ltd has gained around 4.5% in last one month. Meanwhile, Nifty Metal index of which Sanofi India Ltd is a constituent, has gained around 6.06% in last one month and is currently quoting at 12274.35, up 0.21% on the day. The volume in the stock stood at 24278 shares today, compared to the daily average of 16128 shares in last one month.The PE of the stock is 25.94 based on TTM earnings ending December 22.

Sanofi India Ltd gains for fifth session

Sanofi India Ltd gained for a third straight session today. The stock is quoting at Rs 5857.3, up 1.11% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.77% on the day, quoting at 17531.7. The Sensex is at 59617.92, up 0.87%. Sanofi India Ltd has risen around 2.28% in last one month. Meanwhile, Nifty Metal index of which Sanofi India Ltd is a constituent, has risen around 2.74% in last one month and is currently quoting at 12067.95, up 0.52% on the day. The volume in the stock stood at 11051 shares today, compared to the daily average of 14472 shares in last one month.The PE of the stock is 25.35 based on TTM earnings ending December 22.

Sanofi India Ltd spurts 1.11%, gains for third straight session

ICICI Direct recommended hold rating on Sanofi India with a target price of Rs 6270 in its research report dated February 27, 2023.

Hold Sanofi India; target of Rs 6270: ICICI Direct

Sharekhan is bullish on Sanofi India has recommended buy rating on the stock with a target price of Rs 6200 in its research report dated February 24, 2023.

Buy Sanofi India; target of Rs 6200: Sharekhan

Sanofi India Standalone December 2022 Net Sales at Rs 671.90 crore, down 2.33% Y-o-Y

Sanofi India declares final dividend of Rs 194 per share and a special dividend of Rs 183 per share for FY2022.

Sanofi India reports robust Q4 performance with 45% YoY profit growth to Rs 131cr and declares Rs 377 per share dividend

Sanofi India Ltd. engages in the manufacturing and distribution of pharmaceutical drugs. The firm offers its products under the following brands: AllStar, Amaryl M, Amaryl M Forte, Amaryl MV, Apidra, Arava, Augeoz, Brodactam, Cardace, Cardace Protect, Cardace AM, Cardace Meto, Caspercid, Cetapin P, Cetapin XR, Cetapin V, Clexane, Daonil, Daonil M, Frisium, Insuman Rapid, Insuman Comb 25, Insuman Comb 50, Lantus, Lasilactone 50 Lasix, Metosan XR, M-Nem, Amaryl, Renvela Sachets, Semi-Daonil, Targocid, Taxotere, Telsite, Telsite AM, Telsite AM H, Telsite H, Trenta, Vinlep, and Zolineg. It also focuses on the following therapeutic areas: diabetes, cardiology, consumer healthcare, hospital, central nervous system, and anti-histamines. The company was founded on May 2, 1956 and is headquartered in Mumbai, India.

Watchers	44
52-Wk Low	5,042.50
52-Wk High	7,590.00

Market Cap	163.67B
Volume (M)	3,812.00
52-Wk High	7,590.00
52-Wk Low	5,042.50

SANOFI.NSE Sanofi India Ltd

About

Feed

News

Fundamentals